Synergic effect of 3′-azido-3′-deoxythymidine and arsenic trioxide in suppressing hepatoma cells

Anti-Cancer Drugs

Volumn 22, Issue 5, 2011, Pages 435-443

  Chen, Che ^a,b   Zhang, Yingmei ^b   Wang, Yong ^c   Huang, Dejun ^b   Xi, Yaming ^b   Qi, Yongmei ^b  

^a GANSU UNIVERSITY OF CHINESE MEDICINE   (China)

^b LANZHOU UNIVERSITY   (China)

^c North West Normal University   (China)

Author keywords

3 azido 3 deoxythymidine; Arsenic trioxide; cancer treatment; caspase 3; oncology; telomerase

Indexed keywords

ARSENIC TRIOXIDE; CASPASE 3; TELOMERASE; ZIDOVUDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN HEPG2; CELL SURVIVAL; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVITY; HEPATOMA CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTITUBERCULAR AGENTS; APOPTOSIS; ARSENICALS; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CELL GROWTH PROCESSES; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; OXIDES; TELOMERASE; XENOGRAFT MODEL ANTITUMOR ASSAYS; ZIDOVUDINE;

EID: 79955054454     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328340ca08     Document Type: Article

References (59)

1. Di Bisceglie AM. Malignant neoplasms of the liver. In: Schiff ER, Sorrell MF, Maddrey WC, editors. Schiff's diseases of the liver. 8th ed. Philadelphia: Lippincott-Raven Publishers; 1999. pp. 1281-1304.
2. Zhang R, Wang X, Guo L, Xie H. Growth inhibition of BEL-7404 human hepatoma cells by expression of mutant telomerase reverse transcriptase. Int J Cancer 2002; 97:173-179. (Pubitemid 34019952)
3. Van Steensel B, Smogorzewska A, De Lange T. TRF2 protects human telomeres from end-to-end fusions. Cell 1998; 92:401-413. (Pubitemid 28093017)
4. Mo Y, Gan Y, Song S, Johnston J, Xiao X, Wientjes MG, Au JL-S. Simultaneous targetting of telomeres and telomerase as a cancer therapeutic approach. Cancer Res 2003; 63:579-585. (Pubitemid 36158134)
5. Fu W, Begley JG, Killen MW, Mattson MP. Antiapoptotic role of telomerase in pheochromocytoma cells. J Biol Chem 1999; 274:7264-7271.
6. Urquidi V, Tarin D, Goodison S. Role of telomerase in cell senescence and oncogenesis. Annu Rev Med 2000; 51:65-79. (Pubitemid 30216026)
7. Nugent CI, Bosco G, Ross LO, Evans SK, Salinger AP, Moore JK, et al. Telomere maintenance is dependent on activities required for end repair of double-strand breaks. Curr Biol 1998; 8:657-660. (Pubitemid 28257970)
8. Ishikawa T, Kamiyama M, Hisatomi H, Ichikawa Y, Momiyama N, Hamaguchi Y, et al. Telomerase enzyme activity and RNA expression in adriamycinresistant human breast carcinoma MCF-7 cells. Cancer Lett 1999; 141:187-194. (Pubitemid 29261739)
9. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266:2011-2015.
10. Davis AJ, Siu LL. Telomerase: therapeutic potential in cancer. Cancer Invest 2000; 18:269-277. (Pubitemid 30164155)
11. Olivero OA, Anderson LM, Diwan BA, Haines DC, Harbaugh SW, Moskal TJ, et al. Transplacental effects of 3′-azido-2′,3′-dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys. J Natl Cancer Inst 1997; 89:1602-1608. (Pubitemid 27479720)
12. Diwan BA, Riggs CW, Logdson D, Haines DC, Olivero OA, Rice JM, et al. Multiorgan transplacental and neonatal carcinogenicity of 3′-azido- 3′- deoxythymidine in mice. Toxicol Appl Pharmacol 1999; 161:82-99.
13. Falcone A, Lencioni M, Brunetti I, Pfanner E, Allegrini G, Antonuzzo A, et al. Maximum tolerable doses of intravenous zidovudine in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer patients. Clinical evidence of significant antitumor activity and enhancement of zidovudine-induced DNA single strand breaks in peripheral nuclear blood cells. Ann Oncol 1997; 8:539-545. (Pubitemid 127746485)
14. Falcone A, Danesi R, Dargenio F, Pfanner E, Brunetti I, Del Tacca M, et al. Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients. J Clin Oncol 1996; 14:729-736. (Pubitemid 26085516)
15. Zhang T, Wang SS, Hong L, Wang XL, Qi QH. Arsenic trioxide induces apoptosis of rat hepatocellular carcinoma cells in vivo. J Exp Clin Cancer Res 2003; 22:61-68. (Pubitemid 36396659)
16. Vernhet L, Allain N, Le Vee M, Morel F, Guillouzo A, Fardel O. Blockage of multidrug resistance-associated proteins potentiates the inhibitory effects of arsenic trioxide on CYP1A1 induction by polycyclic aromatic hydrocarbons. J Pharmacol Exp Ther 2003; 304:145-155. (Pubitemid 36008922)
17. Wang X, Kong L, Zhao J, Yang P. Arsenic trioxide in the mechanism of drug resistance reversal in MCF-7/ADM cell line of human breast cancer. Zhonghua Zhongliu Zazhi 2002; 24:339-343.
18. Pu YS, Hour TC, Chen J, Huang CY, Guan JY, Lu SH. Arsenic trioxide as a novel anticancer agent against human transitional carcinoma-characterizing its apoptotic pathway. Anticancer Drugs 2002; 13:293-300. (Pubitemid 34492711)
19. Vernhet L, Allain N, Payen L, Anger JP, Guillouzo A, Fardel O. Resistance of human multidrug resistance-associated protein 1-overexpressing lung tumor cells to the anticancer drug arsenic trioxide. Biochem Pharmacol 2001; 61:1387-1391. (Pubitemid 32452354)
20. Gartenhaus RB, Prachand SN, Paniaqua M, Li Y, Gordon LI. Arsenic trioxide cytotoxicity in steroid and chemotherapy-resistant myeloma cell lines: enhancement of apoptosis by manipulation of cellular redox state. Clin Cancer Res 2002; 8:566-572. (Pubitemid 34193978)
21. Kundu SN, Mitra K, Bukhsh AR. Efficacy of a potentized homoeopathic drug (Arsenicum-album-30) in reducing cytotoxic effects produced by arsenic trioxide in mice: III. Enzymatic changes and recovery of tissue damage in liver. Complement Ther Med 2000; 8:76-81. (Pubitemid 30465845)
22. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 1988; 48:589-601. (Pubitemid 18056527)
23. Berenbaum MC. What is synergy? Pharmacol Rev 1989; 41:93-141.
24. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27-55.
25. Mathews V, George B, Lakshmi KM, Viswabandya A, Bajel A, Balasubramanian P, et al. Single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 2006; 107:2627-2632.
26. Mathews V, Balasubramanian P, Shaji RV, George B, Chandy M, Srivastava A. Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: a single center experience. Am J Hematol 2002; 70:292-299. (Pubitemid 34810506)
27. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001; 19:3852-3860. (Pubitemid 32880064)
28. Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999; 94:3315-3324. (Pubitemid 29536124)
29. Lazo G, Kantarjian H, Estey E, Thomas D, O'Brien S, Cortes J. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M.D. Anderson experience. Cancer 2003; 97:2218-2224. (Pubitemid 36444063)
30. Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, Rostami S, Jahani M, Hosseini R, et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol 2006; 17:131-134. (Pubitemid 43033852)
31. Shigeno K, Naito K, Sahara N, Kobayashi M, Nakamura S, Fujisawa S, et al. Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies. Int J Hematol 2005; 82: 224-229. (Pubitemid 41552328)
32. Evens AM, Tallman MS, Gartenhaus RB. The potential of arsenic trioxide in the treatment of malignant disease: past, present and future. Leuk Res 2004; 28:891-900. (Pubitemid 38953641)
33. Kim HR, Kim EJ, Yang SH, Jeong ET, Park C, Kim SJ, et al. Combination treatment with arsenic trioxide and sulindac augments their apoptotic potential in lung cancer cells through activation of caspase cascade and mitochondrial dysfunction. Int J Oncol 2006; 28:1401-1408.
34. Li X, Ding X, Adrian TE. Arsenic trioxide causes redistribution of cell cycle, caspase activation and GADD expression in human colonic, breast and pancreatic cancer cells. Cancer Invest 2004; 22:389-400. (Pubitemid 39310909)
35. Westervelt P, Brown RA, Adkins DR, Khoury H, Curtin P, Hurd D, et al. Sudden death among patients with acute promyeolocytic leukemia treated with arsenic trioxide. Blood 2001; 87:266-271.
36. Lee RK, Cai JP, Deyev V, Gill PS, Cabral L, Wood C, et al. Azidothymidine and interferon-alpha induce apoptosis in herpes virus-associated lymphomas. Cancer Res 1999; 59:5514-5520. (Pubitemid 29526467)
37. Tejera AM, Alonso DF, Gomez DE, Olivero OA. Chronic in vitro exposure to 3′-azido-3′-dideoxythymidine induces senescence and apoptosis and reduces tumorigenicity of metastatic mouse mammary tumor cells. Breast Cancer Res Treat 2001; 65:93-99. (Pubitemid 32193612)
38. Mattson DM, Ahmad IM, Dayal D, Parsons AD, Aykin-Burns N, Li L, et al. Cisplatin combined with zidovudine enhances cytotoxicity and oxidative stress in human head and neck cancer cells via a thiol-dependent mechanism. Free Radic Biol Med 2009; 46:232-237.
39. Johnston JS, Johnson A, Gan Y, Wientjes MG, Au JL-S. Synergy between 3′-azido-3′-deoxythymidine and paclitaxel in human pharynx FaDu cells. Pharm Res 2003; 20:957-961. (Pubitemid 36774264)
40. Browne MJ, Beitz J, Clark JW, Cummings FJ, Weitberg A, Murray C, Darnowski JW. A phase I study of zidovudine (AZT) combined with methotrexate in patients with advanced cancer (abstract). Proc ASCO 1993; 12:A451.
41. Perkins C, Caryn N, Kim L, Fang G, Kapil N, Bhalla L. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemic cells that express Bcr-abl or overexpress MDR, MRP, Bcl-2, or Bcl-Xl. Blood 2000; 95: 1014-1021.
42. Roboz GJ, Dias S, Lam G, Lane WJ, Soignet SL, Warrell RP Jr, Rafii S. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 2000; 96:1525-1531.
43. La Rosée P, Johnson K, O'Dwyer ME, Druker BJ. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Exp Hematol 2000; 30:729-737. (Pubitemid 34831693)
44. La Rosée P, Johnson K, Corbin AS, Stoffregen EP, Moseson EM, Willis S, et al. In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Ablpositive cell lines. Blood 2004; 103:208-217.
45. Lu M, Levin J, Sulpice E, Sequeira-Le Grand A, Alemany M, Caen JP, et al. Effect of arsenic trioxide on viability, proliferation, and apoptosis in human megakaryocytic leukemia cell lines. Exp Hematol 1999; 27: 845-852. (Pubitemid 29231022)
46. 3) on human megakaryocytic leukemia cell lines with a comparison to the effect on other cell lineages. Leuk Lymphoma 2000; 38:151-163.
47. Akao Y, Mizoguchi H, Kojima S, Naoe T, Ohishi N, Yagi K. Arsenic induces apoptosis in B-cell leukaemic cell lines in vitro: activation of caspases and downregulation of Bcl-2 protein. Br J Haematol 1998; 102:1055-1060. (Pubitemid 28410539)
48. Akao Y, Nakagawa Y, Akiyama K. Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro. FEBS Letters 1999; 455:59-62. (Pubitemid 29322782)
49. Solary E, Plenchette S, Sordet O, Rébé C, Ducoroy P, Filomenko R, et al. Mitochondria-targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA differentiated leukemic cells to apoptosis. Blood 2001; 97:3931-3940.
50. Jiang D, Jha N, Boonplueang R, Andersen JK. Caspase-3 inhibition attenuates hydrogen peroxide-induced DNA fragmentation but not cell death in neuronal PC12 cells. J Neurochem 2001; 76:1745-1755. (Pubitemid 32221114)
51. Wolf BB, Schuler M, Echeverri F, Green DR. Caspase-3 is the primary activator of apoptotic DNA fragmentation via DNA fragmentation factor-45/ inhibitor of caspase- activated DNase inactivation. J Biol Chem 1999; 274:30651-30656.
52. Anuradha CD, Kanno S, Hirano S. RGD peptide-induced apoptosis in human leukemia HL-60 cells requires caspase-3 activation. Cell Biol Toxicol 2000; 16:275-283. (Pubitemid 32059898)
53. Turner C, Devitt A, Parker K, MacFarlane M, Giuliano M, Cohen GM, Gregory CD. Macrophage-mediated clearance of cells undergoing caspase-3-independent death. Cell Death Differ 2003; 10:302-312. (Pubitemid 36582368)
54. Maeda H, Hori S, Nishitoh H, Ichijo H, Ogawa O, Kakehi Y, Kakizuka A. Tumor growth inhibition by arsenic trioxide in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res 2001; 61:5432-5440. (Pubitemid 32694923)
55. Monzen H, Griffin RJ,Williams BW, Amano M, Ando S, Hasegawa T. Study of arsenic trioxide-induced vascular shutdown and enhancement with radiation in solid tumor. Radia Med 2004; 22:205-211. (Pubitemid 39264796)
56. Kito M, Matsumoto K,Wada N, Sera K, Futatsugawa S, Naoe T, Nozawa Y. Antitumor effect of arsenic trioxide in murine xenograft model. Cancer Sci 2003; 94:1010-1014. (Pubitemid 37508985)
57. Xu HY, Yang YL, Liu SM, Bi L, Chen SX. Effect of arsenic trioxide on human hepatocarcinoma in nude mice. World J Gastroenterol 2004; 10:3677-3679. (Pubitemid 39619293)
58. Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM, Shi JY. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 2004; 101:5328-5335. (Pubitemid 38481160)
59. Liu B, Pan S, Dong X, Qiao H, Jiang H, Krissansen GW, Sun X. Opposing effects of arsenic trioxide on hepatocellular carcinomas in mice. Cancer Sci 2006; 97:675-681. (Pubitemid 44056616)